NXP800 yields neither severe thrombocytopenia, nor any responses.
ApexOnco Front Page
Recent articles
For $500m the big pharma group secures LaNova's anti-VEGF x PD-1 antibody.
The EU recommendation for odronextamab comes after a US rejection in March.
Farletuzumab ecteribulin follows its parent MAb with a setback, spelling possible bad news for Sutro.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
But ficerafusp is limited to HPV-negative disease, and petosemtamab’s safety looks better.
The group plays down upcoming interim analysis, but still hopes for accelerated approval.
A complete response letter for Merck & Co and Daiichi’s patritumab deruxtecan might not be fatal, but it’s certainly embarrassing.
